Comparison of Two Stereotactic Radiotherapy Regimens for Brain Metastases: Is higher always better ?

Clicks: 1
ID: 313879
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #55 of 104 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Stereotactic radiosurgery (SRS) has become a preferred treatment for brain metastases (BMs) due to its precision, minimizing neurocognitive side effects compared to whole-brain radiotherapy. However, the optimal dose-fractionation regimen for balancing local tumor control and minimizing radiation necrosis (RN) remains debated. This study compares two commonly used fractionated SRS regimens: 23.1Gy in 3 fractions and 27Gy in 3 fractions. Materials and Methods This retrospective study included 1,348 BMs treated with fractionated SRS between 2014 and 2023. Treatment planning used inhomogeneous dose delivery on a TrueBeam™ STX linac, delivering either 23.1Gy/3 fractions or 27Gy/3 fractions to the periphery (33Gy to the isocenter). Outcomes included local relapse-free survival (LRFS), RN-free survival (RNFS) and symptomatic RN-free survival (SRNFS), analyzed using Kaplan-Meier estimates. Impact of the main clinical factors (BMs volume, histology of the primary, concomitant systemic therapies and history of radiotherapy) were analyzed using univariate and multivariate Cox regression models. Results Median follow-up was 12.0 months for LRFS and 11.0 months for RNFS. The 27Gy regimen showed a non-significant improvement in LRFS (HR 0.66, CI95% 0.43–1.01) but significantly increased the risk of both RN (HR 2.29, CI95% 1.60–3.26) and symptomatic RN (HR 3.74, CI95% 1.93–7.26). On multivariate analysis, choice of the SRS protocol was an independent predictor of RN. Conclusion The 27Gy regimen offers modest improvements in local control but significantly increases the risk of both RN and symptomatic RN. These results emphasize the need for personalized SRS regimens and further exploration of dose optimization strategies to improve therapeutic outcomes.
Reference Key
openalex_W7160887144 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vincent Bourbonne, Moncef Morjani, Brieg Dissaux, Marie Cabaret, Solène Querellou, Romuald Seizeur, R. Descourt, Olivier Pradier, Gurvan Dissaux, François Lucia
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag126
URL
https://doi.org/10.1093/noajnl/vdag126
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.